AT 1501, Part 1: The Science Behind the Drug
Aug 11, 2020•30 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
AT-1501 is an ALS treatment invented by ALS TDI. In 2018, became the first drug invented by a non-profit biotech to be tested in humans. In November of 2019, it successfully completed a Phase 1 clinical trial, and a Phase 2 trial is upcoming.
Today, in part one of a new series about the science behind AT-1501, we’re joined by ALS TDI CEO Dr. Steve Perrin, who will walk us through the first steps in the process that lead to the invention of this drug – the research into the mechanisms of how ALS effects the body, the experiments conducted in the lab, and the identification of a target to treat with a new drug.
Support the show: https://www.als.net/donate/
See omnystudio.com/listener for privacy information.
For the best experience, listen in Metacast app for iOS or Android